TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cumulative probability of recurrence through 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Rate of response or remission at month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall discontinuation rates
Endpoint domain: Adverse events/effects
Primary endpoint: Mean onset time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean working time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of MB for specialized intestinal metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sensitivity of MB for dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clearance of H. pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: duration of survey completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection of premalignant gastric mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum C-reactive protein/albumin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of cardiovascular, ocular, or renal events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: variance reduction in chronicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variance reduction in time course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variance reduction in health care use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variance reduction in patient impact
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Good neurologic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacokinetics of 5-FU and eniluracil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence of dosing forms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity levels
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived doctor support
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Acuity (VA) ≥ 0.1 logMAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Visual Acuity (BVA) comparison to subjective refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oblique astigmatism component J45
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dizziness Handicap Index (DHI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refixation saccades organization pattern (PR score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to ED disposition
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to OR
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Discharge time after negative IV scans
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Need for additional PRO infusions
Endpoint domain: Adverse events/effects
Primary endpoint: Requirement for analgesic agents
Endpoint domain: Adverse events/effects
Primary endpoint: Requirement for artificial ventilation
Endpoint domain: Adverse events/effects
Primary endpoint: Functional motor performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: memory ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy in treatment of hypochondriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QALY gains
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incremental cost utility ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in EF
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success rate for complete cycloplegia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NLR as a predictor of subclinical atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CIMT values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: visual and vestibular ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per consultation achieved
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of asthma patients reviewed
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Sex communication outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum cTnI levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Rate (HR) and systolic arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Extubation times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rates for selective bile duct cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PEP rates
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity for histologically confirmed CIN lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity for histologically confirmed CIN lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: UPDRS 'on' motor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean transferrin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Favorable outcomes (mRS scores 0‐2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of neurological deterioration
Endpoint domain: Adverse events/effects
Primary endpoint: NPI total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor block incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean operating room time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post-anaesthesia care unit (PACU) time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Nausea and vomiting in the PACU
Endpoint domain: Adverse events/effects
Primary endpoint: modeled symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: misattributed symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: <50 copies/mL response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: <400 copies/mL response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative suppression (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Wake After Sleep Onset (WASO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep and subcutaneous tissue outcomes
Primary endpoint: Sleep Efficiency (SE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep and subcutaneous tissue outcomes
Primary endpoint: Cocontraction index values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional stability boundary for forward
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suppression of serum CTX-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: incidence of transient neurologic symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Suppression of skin test reactions to histamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: hunger levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: eating timing
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: LTD-like MEP depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urea concentration in dialysate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose concentration in dialysate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lactate concentration in dialysate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain scores during labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of cesarean section deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incident Heart Failure (HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional improvement (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical site quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DQOL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: hot flash severity scores reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of women reporting at least 50% decrease in hot flash frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of biliary pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of pathological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence rate of ischaemic stroke/TIA/TE
Endpoint domain: Mortality/survival
Primary endpoint: Adverse outcome in hemodialysis patients
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative Harris hip scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative visual analog scale (VAS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right atrial pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased urine output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Local recurrence within 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Voice assessment post-treatment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Median pain scoring by VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median procedural entry time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of treatment with antidepressants on depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardio- and cerebrovascular events (MACCE)
Endpoint domain: Mortality/survival
Primary endpoint: Atheroma volume changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional outcome (modified Rankin Scale 0 to 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin resistance (measured by glucose infusion rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean absolute bioavailability of sildenafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax reduction due to food
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC reduction due to food
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anastomotic leaks incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Anastomotic stricture rate
Endpoint domain: Adverse events/effects
Primary endpoint: Gastroesophageal reflux occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: plasma concentration of branched chain amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma concentration of essential amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean absorption percentage of cafestol and kahweol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean excretion of glucuronidated plus sulphated conjugates in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completed vision screening rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referrals to eye care specialists
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: TnI concentrations above the 99th centile upper reference limit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak serum TnI concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak NT-proBNP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lateral translation of the distal tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Micromotion after weight bearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete success at target IOP (<=21 mm Hg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Joint Space Width (JSW) difference between repeat films
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint pain frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint swelling frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity scores for joint symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-procedure pain score after 15 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infection of the procedure site
Endpoint domain: Adverse events/effects
Primary endpoint: number of ischemic wall segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in antibiotics prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Optimal platelet transfusion support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Abstinence (30-day point prevalence)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: functional independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall response rate (CR + PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to best response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum contraceptive use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 10-year success rate of corneal grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial concentrations of factor VII coagulant activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: thromboxane B(2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mid-thigh muscle cross-sectional area increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cumulative probability of recurrence of ocular HSV disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of recurrent HSV epithelial keratitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of recurrent stromal keratitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lesion conspicuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fecal contamination
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate and severe contamination
Endpoint domain: Adverse events/effects
Primary endpoint: Nausea, vomiting, abdominal distension, fatigue, palpitation
Endpoint domain: Adverse events/effects
Primary endpoint: WMFT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: NHPT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: incremental reduction of one glass of alcohol per week
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incremental reduction of one binge drinking occasion per 30 days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: months in remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreases in psychotic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreases in affective symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vaccine serotype pneumococcal carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in PPD (probing pocket depth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of N20 component of SEPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptom severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy for controlling symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Platelet recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of platelets transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sinus node dysfunction (SND)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma concentrations of BDNF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Der p 1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Door-to-recanalization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of MT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Door-to-first angiographic image time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in proinflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Endothelial dysfunction prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of clinical union during 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VAS from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject satisfaction with treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Successful IV insertion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: rate of good prognosis
Endpoint domain: Mortality/survival
Primary endpoint: Pain during physiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ODI outcome <= 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cardiomyocytes expressing ROS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of TNF‐
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of SOD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of propofol-induced pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA level decrease by > or =50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in pain over time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: coronary flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: flow resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acne severity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PPS (Perceived Stress Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of excessive drinkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weekly alcohol intake reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Credibility scores for perceived ease of dental treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Desaturation events ≤94%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes